Abaloparatide vs Teriparatide: What the Research Shows
Abaloparatide and Teriparatide side by side: what they are, how they are regulated and what is still unknown.
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
[class][status]AbaloparatideParathyroid hormone-related peptide analog sold as Tymlos; the label states it reduces the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.[3]
[class][status]TeriparatideParathyroid hormone analog sold as Forteo; the label states it reduces the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.[4]
Quick verdict
Summary of studies, not a recommendationWhere the research points
Consider Abaloparatide if…
- you want an FDA-approved product: Tymlos (abaloparatide) is indicated for postmenopausal women with osteoporosis at high risk for fracture[3]
Consider Teriparatide if…
- you want an FDA-approved product: Forteo (teriparatide) is indicated for postmenopausal women with osteoporosis at high risk for fracture[4]
- you want the label that also covers glucocorticoid-induced osteoporosis: Forteo is indicated for men and women with osteoporosis associated with sustained systemic glucocorticoid therapy[4]
What they have in common
- In the ACTIVE trial, hypercalcemia occurred in 3.4% with abaloparatide vs 6.4% with teriparatide[2]
Neither is FDA approved for any use in people. Status labels come from public FDA and WADA records; see the sources below.
Side by side
Spec comparison
Showing 1 of 8 fields where the two differ. Class, FDA status, PCAC vote, Jul 2026, WADA, Half-life, Evidence strength, Typical study doses are the same or both unknown.
| Field | Abaloparatide | Teriparatide |
|---|---|---|
| Class | [class] | [class] |
| Also called | Tymlos | — |
| FDA status | [status] | [status] |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | No WADA record in our data | No WADA record in our data |
| Half-life | [half-life by route] | [half-life by route] |
| Evidence strength | [evidence grade] | [evidence grade] |
| Typical study doses | [dose range] | [dose range] |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Sources
- 1PubMed search: (abaloparatide[tiab] OR Tymlos[tiab]) AND (teriparatide[tiab] OR Forteo[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.JAMA · 2016PMID 27533157Accessed 2 Oct 2026
- 3TYMLOS prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 4FORTEO prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.